Aldeyra Therapeutics (ALDX) Operating Leases (2019 - 2025)

Aldeyra Therapeutics (ALDX) has reported Operating Leases for 6 consecutive years, with $72536.0 the latest figure, recorded in Q3 2025.

• For the quarter ending Q3 2025, Operating Leases rose 3.28% year-over-year to $72536.0; the trailing twelve-month figure through Sep 2025 stood at $72536.0 (up 3.28% YoY), and the FY2023 full-year result was $271631.0, changed N/A from the prior year.
• Operating Leases fell to $72536.0 in Q3 2025 per ALDX's latest filing, from $143447.0 in the prior quarter.
• Across five years, Operating Leases topped out at $271631.0 in Q4 2023 and bottomed at $63325.0 in Q1 2022.
• Historically, Operating Leases has averaged $148868.0 across 5 years, with a median of $141170.0 in 2024.
• The widest YoY moves for Operating Leases: up 3.28% in 2025, down 3.28% in 2025.
• Over 5 years, Operating Leases stood at $125232.0 in 2021, then plunged by 49.43% to $63325.0 in 2022, then jumped by 328.95% to $271631.0 in 2023, then sank by 74.14% to $70234.0 in 2024, then grew by 3.28% to $72536.0 in 2025.
• According to Business Quant data, Operating Leases over the past three periods registered $72536.0, $143447.0, and $212769.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.